Alirocumab cuts cardiac mortality in patients with diabetes

Findings provide 'greater reassurance' of glycaemic safety of PCSK9 inhibitors, study authors say

The PCSK9 inhibitor alirocumab conveys almost double the cardio-protective benefit in patients with diabetes following acute coronary syndrome than those without diabetes, a large international trial has shown.


The study, funded by Sanofi and Regeneron Pharmaceuticals, also suggests that an aggressive lipid-lowering treatment with an LDL cholesterol concentration target of 0.65-1.30mmol/L does not increase the risk of new-onset diabetes, the researchers say.

In the multicentre ODYSSEY OUTCOMES study, 18,900 patients (aged 50-66) hospitalised with ACS 1-12